Worldwide Oral Cancer Treatment Industry to 2030 - Featuring Cipla, Sanofi and Teva Pharmaceuticals Industries Among Others - ResearchAndMarkets.com

The "Oral Cancer Treatment Market by Treatment, Age Group and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

The global oral cancer treatment market was valued at $ 1,710.53 million 2020, and is projected to reach $ 2,729.72 Million by 2030 registering a CAGR of 4.80% from 2021 to 2030.

Oral cancer is a type of head and neck cancer that manifests itself in the mouth as a tumor. The tongue, lips, cheeks, gums, tonsils, and salivary glands are the most common sites for oral or mouth cancer. Oral cancers are classified as either benign or malignant. Surgical removal of benign tumors is possible. Squamous cell carcinoma accounts for 90% of malignant oral malignancies, which can spread to other parts of the body.

Furthermore, according to the Oral Cancer Foundation, every year around 53,000 new oral cancer cases are diagnosed and more than 9,750 people succumb to the disease in the U.S. Oral cancer accounts for 4% of total cancer cases and causes 2.2% deaths in the U.S. In western countries, prevalence of oral cancer is 2% to 6% of the total cancer cases. In addition, in Asia-Pacific, the oropharyngeal cancer is more common among men than women. According to the National Cancer Institute, 60% of people with oral cancer survive for five years or more and 70% to 90% of people with Stage 1 or 2 cancer survive for more than 5 years.

The growth of the global oral cancer treatment market is majorly driven by rise in prevalence of oral or mouth cancer globally is a major factor fostering the growth of the market. Rise in expenditure on the development of healthcare infrastructure, increase in consumption of tobacco products such as cigarettes, cigars, pipes and chewing tobacco and upsurge in the special designation from regulatory authorities are other factors also fostering the growth of the market. Increase in personal disposable income coupled with rise in prevalence of papillomavirus infection is other indirect determinant that will create lucrative market growth opportunities.

However, lack of awareness about the oral cancer in the backward and underdeveloped areas will hamper the market growth. Risk of recurrence even after the treatment will also hamper the market growth rate.

The oral cancer treatment market is segmented on the basis of treatment, age group, end user, and region. Depending on treatment, the market is classified into chemotherapy, immunotherapy, targeted therapy. The age group segment is further categorized into 30-49, 50-69 and 70<. By end user, it is fragmented into hospital pharmacies, drug stores & retail pharmacies, online stores. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

• The study provides an in-depth analysis of the global oral cancer treatment market along with the current trends and future estimations to elucidate the imminent investment pockets.
• A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
• Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the key segments of the industry helps understand the applications and products of oral injury used across the globe.
• Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Market Dynamics

Drivers

• Rise in prevalence of oral cancer
• Surge in global geriatric population
• Increase in government expenditure on healthcare

Restraint

• Adverse effects associated with the use cancer drugs

Opportunities

• High growth potential in untapped emerging economies
• Increase in number of pipeline drugs

Key Market Segments

By Treatment

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• By Age Group
• 30-49
• 50-69
• 70<

By End User

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Stores

By Region

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Japan
• China
• Australia
• India
• South Korea
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA

Companies Mentioned

• Bristol-Myers Squibb Company
• Cipla Inc.
• Eli-Lilly F.
• Hoffmann-La Roche
• Fresenius Kabi AG
• Intas Pharmaceuticals Ltd
• Merck & Co.Inc.
• Sanofi
• Teva Pharmaceuticals Industries Ltd
• Viatris

For more information about this report visit https://www.researchandmarkets.com/r/dnda3b

View source version on businesswire.com: https://www.businesswire.com/news/home/20220303005865/en/